New urine test could spot kidney danger in ICU patients early

NCT ID NCT06652100

Ongoing Diagnosis Sponsor: BioPorto Diagnostics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study involves 800 adults in intensive care who provide urine samples to test a new lab test called ProNephro AKI (NGAL). The goal is to find the right cutoff value that best identifies patients at risk for moderate to severe acute kidney injury within 48-72 hours. The test measures a protein in urine that rises when kidneys are stressed. If the cutoff is established, it could help doctors act faster to protect kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ProNephro AKI (NGAL) urine test
What this could lead to: If successful, this could give doctors a reliable urine test to quickly identify ICU patients at high risk for serious kidney injury, allowing earlier intervention.
What could go wrong: This is an observational study to establish a cutoff value, not a treatment trial. The test may not prove accurate enough in all patient groups, and results may not change outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Columbia University

New York, New York, 10032, United States
Johns Hopkins University

Baltimore, Maryland, 21224, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
The University of Alabama

Birmingham, Alabama, 35233, United States
UC Davis

Sacramento, California, 95817, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of New Mexico

Albuquerque, New Mexico, 87131, United States
Wake Forest University

Winston-Salem, North Carolina, 27109, United States
Yale University

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.